BioSpace News Archive

Protagen Protein Services (PPS) today announced that it will merge with GeneWerk, an Ampersand portfolio company.

Gravity Diagnostics is a CLIA certified, and CAP-accredited laboratory licensed in all 50 states that processed nearly 50% of the Commonwealth of Kentucky COVID-19 gold standard PCR tests during the pandemic.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced the appointment of Pablo Urbaneja as Senior Vice President, Corporate Development.

Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of its wholly-owned subsidiary, Myriad RBM, Inc. to Q2 Solutions, a leading global clinical trial laboratory services organization, and a wholly owned subsidiary of IQVIA.

Tempest Therapeutics, Inc., a clinical-stage oncology company developing potentially first-in-class therapeutics that combine both targeted and immune-mediated mechanisms, announced the appointment of 20-year industry veteran Christine Pellizzari to the company’s Board of Directors.

Varex Imaging Corporation announced the addition of the LUMEN 4336W digital radiography detector to Varex’s product line.

CONMED Corporation announced that it will report financial results for the second quarter 2021 after the market close on Wednesday, July 28, 2021.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the company plans to voluntarily withdraw the U.S. accelerated approval indication for KEYTRUDA for the treatment of patients with recurrent locally advanced or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 [combined positive score (CPS ≥1)] as determined by a U.S. Food and Drug Administration (FDA)-approved test,

Atara Biotherapeutics, Inc., a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the Company has joined the Rare Disease Company Coalition.

Dicerna Pharmaceuticals, Inc. announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 31,875 shares of common stock and 7,125 restricted stock units to be distributed to one new employee with a grant date of July 1, 2021.